Loading...

Assembly Biosciences

BST:V7B1
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
V7B1
BST
$401M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Assembly Biosciences has significant price volatility in the past 3 months.
V7B1 Share Price and Events
7 Day Returns
0.5%
BST:V7B1
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-61.4%
BST:V7B1
-5.6%
DE Biotechs
-4.5%
DE Market
V7B1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Assembly Biosciences (V7B1) 0.5% -9.5% -22.3% -61.4% 176% 274.3%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • V7B1 underperformed the Biotechs industry which returned -5.6% over the past year.
  • V7B1 underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
V7B1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Assembly Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Assembly Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €13.96.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Assembly Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Assembly Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:V7B1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.98
NasdaqGS:ASMB Share Price ** NasdaqGS (2019-04-25) in USD $15.68
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Assembly Biosciences.

BST:V7B1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ASMB Share Price ÷ EPS (both in USD)

= 15.68 ÷ -3.98

-3.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Assembly Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Assembly Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Assembly Biosciences's expected growth come at a high price?
Raw Data
BST:V7B1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
3.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Assembly Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Assembly Biosciences's assets?
Raw Data
BST:V7B1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $8.26
NasdaqGS:ASMB Share Price * NasdaqGS (2019-04-25) in USD $15.68
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
BST:V7B1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ASMB Share Price ÷ Book Value per Share (both in USD)

= 15.68 ÷ 8.26

1.9x

* Primary Listing of Assembly Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Assembly Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Assembly Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Assembly Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Assembly Biosciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
3.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Assembly Biosciences expected to grow at an attractive rate?
  • Assembly Biosciences's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Assembly Biosciences's earnings growth is positive but not above the Germany market average.
  • Assembly Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:V7B1 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:V7B1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 3.3%
BST:V7B1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 50.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:V7B1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:V7B1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 553 162 1
2022-12-31 132 -170 2
2021-12-31 14 -182 -228 1
2020-12-31 13 -148 -168 3
2019-12-31 14 -88 -127 5
BST:V7B1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 15 -65 -91
2018-09-30 14 -58 -68
2018-06-30 13 -52 -58
2018-03-31 12 -49 -45
2017-12-31 9 2 -43
2017-09-30 6 1 -51
2017-06-30 3 4 -51
2017-03-31 1 9 -47
2016-12-31 -35 -44
2016-09-30 -29 -40
2016-06-30 -27 -36
2016-03-31 -24 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Assembly Biosciences's earnings are expected to grow by 3.3% yearly, however this is not considered high growth (20% yearly).
  • Assembly Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:V7B1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Assembly Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:V7B1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.57 4.57 4.57 1.00
2022-12-31 -5.21 -4.57 -5.85 2.00
2021-12-31 -7.58 -6.50 -8.66 2.00
2020-12-31 -5.93 -4.85 -7.94 4.00
2019-12-31 -4.73 -3.74 -5.99 6.00
BST:V7B1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.98
2018-09-30 -3.19
2018-06-30 -3.02
2018-03-31 -2.44
2017-12-31 -2.41
2017-09-30 -2.97
2017-06-30 -2.93
2017-03-31 -2.74
2016-12-31 -2.57
2016-09-30 -2.35
2016-06-30 -2.06
2016-03-31 -1.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Assembly Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Assembly Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Assembly Biosciences has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Assembly Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Assembly Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Assembly Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Assembly Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Assembly Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Assembly Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Assembly Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:V7B1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 14.80 -90.75 30.50
2018-09-30 14.38 -67.60 30.99
2018-06-30 12.76 -58.33 23.12
2018-03-31 11.90 -45.13 18.68
2017-12-31 9.02 -42.81 17.02
2017-09-30 5.70 -51.35 15.27
2017-06-30 3.04 -50.65 13.93
2017-03-31 0.68 -47.20 13.07
2016-12-31 -44.26 12.19
2016-09-30 -40.46 11.89 5.23
2016-06-30 -35.51 11.54 9.86
2016-03-31 -32.30 11.09 14.52
2015-12-31 -28.45 11.30
2015-09-30 -26.93 11.66 16.11
2015-06-30 -31.34 16.55 15.15
2015-03-31 -26.86 15.47 11.58
2014-12-31 -23.79 13.24 10.72
2014-09-30 -23.61 10.87 12.90
2014-06-30 -17.47 4.66 12.98
2014-03-31 -19.75 4.55 15.39
2013-12-31 -19.40 4.58 15.03
2013-09-30 -17.15 4.72 12.61
2013-06-30 -17.62 4.72 13.05
2013-03-31 -20.34 4.73 15.70
2012-12-31 -24.79 5.34 19.51
2012-09-30 -39.86 5.61 34.31
2012-06-30 -40.30 6.31 33.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Assembly Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Assembly Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Assembly Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Assembly Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Assembly Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Assembly Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Assembly Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Assembly Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Assembly Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Assembly Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Assembly Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Assembly Biosciences Company Filings, last reported 3 months ago.

BST:V7B1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 210.65 0.00 218.08
2018-09-30 229.43 0.00 233.94
2018-06-30 89.10 0.00 92.67
2018-03-31 102.38 0.00 109.16
2017-12-31 113.12 0.00 119.95
2017-09-30 47.13 0.00 66.30
2017-06-30 56.54 0.00 75.58
2017-03-31 67.89 0.00 90.92
2016-12-31 79.88 0.00 52.96
2016-09-30 90.04 0.00 58.65
2016-06-30 100.56 0.00 63.55
2016-03-31 109.28 0.00 58.32
2015-12-31 118.74 0.00 67.66
2015-09-30 125.40 0.00 65.80
2015-06-30 130.87 0.00 70.73
2015-03-31 124.62 0.00 96.05
2014-12-31 58.57 0.00 29.09
2014-09-30 47.20 0.00 17.93
2014-06-30 20.29 0.00 21.32
2014-03-31 22.44 0.00 23.64
2013-12-31 24.49 0.00 27.06
2013-09-30 30.05 0.00 32.22
2013-06-30 31.09 0.00 33.49
2013-03-31 35.13 0.00 36.87
2012-12-31 17.81 0.00 20.49
2012-09-30 21.00 0.00 23.56
2012-06-30 25.62 0.00 28.84
  • Assembly Biosciences has no debt.
  • Assembly Biosciences has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Assembly Biosciences has sufficient cash runway for more than 3 years based on current free cash flow.
  • Assembly Biosciences has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 42.3% each year.
X
Financial health checks
We assess Assembly Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Assembly Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Assembly Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Assembly Biosciences dividends.
If you bought €2,000 of Assembly Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Assembly Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Assembly Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:V7B1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:V7B1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Assembly Biosciences has not reported any payouts.
  • Unable to verify if Assembly Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Assembly Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Assembly Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Assembly Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Assembly Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Assembly Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Assembly Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Derek Small
COMPENSATION $1,438,725
AGE 42
TENURE AS CEO 4.2 years
CEO Bio

Mr. Derek A. Small is a Co-Founder of Assembly Biosciences, Inc. Mr. Small has been Chief Executive Officer and President at Assembly Biosciences, Inc. since February 17, 2015 and July 11, 2014 respectively. He has been Director of Assembly Biosciences, Inc. since July 11, 2014. Mr. Small served as the Chief Operating Officer and Budget Chief of Assembly Biosciences, Inc. since July 11, 2014. He served as the President at Luson Bioventures, LLC. He served as Head of Business and Corporate Development of Semafore Pharmaceuticals, Inc. From January 2009 to April 2012, Mr. Small also served as a Founding Director, President, and Chief Executive Officer of Coferon, Inc. and served as its Acting Chief Executive Officer. From March 2008 to January 2014, Mr. Small served as a Founding Director, President, and Chief Executive Officer of Naurex, Inc. He was an associate at EMC2 Corporation with responsibilities spanning business development, sales and venture capital channels; and Morgan Stanley previous to that. He is a Director of BioCrossroads. He serves as Director of the Association of Strategic Alliance Professionals (ASAP) Chicago and Midwest chapter and member of ASAP's Global Bio-Pharma Council. He served as a Director of Naurex Inc. He received his BS in Business and Marketing at Franklin College. In addition to his studies in the US, he studied Global Business and International Marketing in England at Harlaxton College.

CEO Compensation
  • Derek's compensation has increased whilst company is loss making.
  • Derek's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Assembly Biosciences management team in years:

1.6
Average Tenure
47
Average Age
  • The average tenure for the Assembly Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Derek Small

TITLE
Co-Founder
COMPENSATION
$1M
AGE
42
TENURE
4.2 yrs

Uri Lopatin

TITLE
Co-Founder
COMPENSATION
$728K
AGE
46
TENURE
4.8 yrs

Rich Colonno

TITLE
Executive VP & Chief Scientific Officer of Virology Operations
COMPENSATION
$6M
AGE
68
TENURE
1.3 yrs

Thomas Rollins

TITLE
Executive Officer
COMPENSATION
$652K
AGE
62
TENURE
1 yrs

David Barrett

TITLE
Consultant
COMPENSATION
$1M
AGE
42
TENURE
1.3 yrs

Adam Zlotnick

TITLE
Co-Founder

Graham Cooper

TITLE
CFO & COO
AGE
48
TENURE
1.1 yrs

Lauren Glaser

TITLE
Vice President of Investor Relations & Corporate Affairs

Elizabeth Lacy

TITLE
General Counsel
TENURE
3.3 yrs

Micah MacKison

TITLE
Senior Vice President of Corporate Development & Strategy
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Assembly Biosciences board of directors in years:

4.8
Average Tenure
65
Average Age
  • The tenure for the Assembly Biosciences board of directors is about average.
Board of Directors

Bill Ringo

TITLE
Non-Executive Chairman
COMPENSATION
$213K
AGE
73
TENURE
4.2 yrs

Derek Small

TITLE
Co-Founder
COMPENSATION
$1M
AGE
42
TENURE
4.8 yrs

Adam Zlotnick

TITLE
Co-Founder
TENURE
4.8 yrs

Myron Holubiak

TITLE
Lead Independent Director
COMPENSATION
$185K
AGE
71

Mark Auerbach

TITLE
Independent Director
COMPENSATION
$190K
AGE
80
TENURE
8.4 yrs

Richard DiMarchi

TITLE
Independent Director
COMPENSATION
$180K
AGE
65
TENURE
4.8 yrs

Alan Lewis

TITLE
Director
COMPENSATION
$185K
AGE
72
TENURE
3.3 yrs

Tony Altig

TITLE
Independent Director
COMPENSATION
$183K
AGE
62
TENURE
7.3 yrs

Sue Mahony

TITLE
Independent Director
COMPENSATION
$607K
AGE
53
TENURE
1.3 yrs

Helen Kim

TITLE
Independent Director
AGE
56
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Jul 18 Buy Derek Small Individual 19. Jul 18 19. Jul 18 2,400 €36.01 €85,813
X
Management checks
We assess Assembly Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Assembly Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company’s microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn’s disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Details
Name: Assembly Biosciences, Inc.
V7B1
Exchange: BST
Founded: 2005
$359,676,806
25,549,757
Website: http://www.assemblybio.com
Address: Assembly Biosciences, Inc.
11711 North Meridian Street,
Suite 310,
Carmel,
Indiana, 46032,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ASMB Common Stock Nasdaq Global Select US USD 17. Dec 2010
BST V7B1 Common Stock Boerse-Stuttgart DE EUR 17. Dec 2010
Number of employees
Current staff
Staff numbers
95
Assembly Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:21
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/22
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.